Correlation between smoking history and molecular pathways in sporadic colorectal cancer: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 3241-3257

  Chen, Ke ^a   Xia, Guanggai ^b   Zhang, Changhua ^b   Sun, Yunwei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Genetic; Molecular pathways; Smoking; Sporadic colorectal cancer; Therapy

Indexed keywords

ARTICLE; CELL HETEROGENEITY; COLORECTAL CANCER; DATA EXTRACTION; DISEASE ASSOCIATION; DNA METHYLATION; GENE MUTATION; HUMAN; META ANALYSIS; SMOKING; TUMOR SUPPRESSOR GENE;

EID: 84929155434     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Lao VV and Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 686-700.
2. Bakhoum SF and Compton DA. Chromosomal instability and cancer: a complex relationship with therapeutic potential. J Clin Invest 2012; 122: 1138-1143.
3. Ogino S and Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008; 10: 13-27.
4. Sharma S, Kelly TK and Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
5. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507.
6. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
7. Segditsas S and Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006; 25: 7531-7537.
8. Vousden KH and Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137: 413-431.
9. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F and Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379.
10. Chen MB, Wu XY, Yu R, Li C, Wang LQ, Shen W and Lu PH. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS One 2012; 7: e45388.
11. Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi C, Antoniotti C, Bergamo F, Lonardi S, Zagonel V, Simi P, Fontanini G and Falcone A. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014; 50: 57-63.
12. Harada S and Korf BR. Overview of molecular genetic diagnosis. Curr Protoc Hum Genet 2013; Chapter 9: Unit9 1.
13. Personal habits and indoor combustions. Volume 100 E. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012; 100: 1-538.
14. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 3: 733-744.
15. Tomlinson I, Halford S, Aaltonen L, Hawkins N and Ward R. Does MSI-low exist? J Pathol 2002; 197: 6-13.
16. DerSimonian R and Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
17. Mantel N and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
18. Phipps AI, Shi Q, Newcomb PA, Nelson GD, Sargent DJ, Alberts SR and Limburg PJ. Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147. J Clin Oncol 2013; 31: 2016-2023.
19. Sinha R, Hussain S, Mehrotra R, Kumar RS, Kumar K, Pande P, Doval DC, Basir SF and Bharadwaj M. Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population. PLoS One 2013; 8: e60142.
20. Burnett-Hartman AN, Newcomb PA, Potter JD, Passarelli MN, Phipps AI, Wurscher MA, Grady WM, Zhu LC, Upton MP and Makar KW. Genomic Aberrations Occurring in Subsets of Serrated Colorectal Lesions but not Conventional Adenomas. Cancer Res 2013; 73: 2863-2872.
21. Samadder NJ, Vierkant RA, Tillmans LS, Wang AH, Lynch CF, Anderson KE, French AJ, Haile RW, Harnack LJ, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR and Limburg PJ. Cigarette smoking and colorectal cancer risk by KRAS mutation status among older women. Am J Gastroenterol 2012; 107: 782-789.
22. Naghibalhossaini F, Zamani M, Mokarram P, Khalili I, Rasti M and Mostafavi-Pour Z. Epigenetic and genetic analysis of WNT signaling pathway in sporadic colorectal cancer patients from Iran. Mol Biol Rep 2012; 39: 6171-6178.
23. Gay LJ, Mitrou PN, Keen J, Bowman R, Naguib A, Cooke J, Kuhnle GG, Burns PA, Luben R, Lentjes M, Khaw KT, Ball RY, Ibrahim AE and Arends MJ. Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk study. J Pathol 2012; 228: 405-415.
24. Gay LJ, Arends MJ, Mitrou PN, Bowman R, Ibrahim AE, Happerfield L, Luben R, McTaggart A, Ball RY and Rodwell SA. MLH1 promoter methylation, diet, and lifestyle factors in mismatch repair deficient colorectal cancer patients from EPIC-Norfolk. Nutr Cancer 2011; 63: 1000-1010.
25. Rozek LS, Herron CM, Greenson JK, Moreno V, Capella G, Rennert G and Gruber SB. Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 838-843.
26. Park JY, Mitrou PN, Keen J, Dahm CC, Gay LJ, Luben RN, McTaggart A, Khaw KT, Ball RY, Arends MJ and Rodwell SA. Lifestyle factors and p53 mutation patterns in colorectal cancer patients in the EPIC-Norfolk study. Mutagenesis 2010; 25: 351-358.
27. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Harnack LJ, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR and Limburg PJ. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 2010; 102: 1012-1022.
28. Poynter JN, Haile RW, Siegmund KD, Campbell PT, Figueiredo JC, Limburg P, Young J, Le Marchand L, Potter JD, Cotterchio M, Casey G, Hopper JL, Jenkins MA, Thibodeau SN, Newcomb PA and Baron JA. Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev 2009; 18: 2745-2750.
29. Curtin K, Samowitz WS, Wolff RK, Herrick J, Caan BJ and Slattery ML. Somatic alterations, metabolizing genes and smoking in rectal cancer. Int J Cancer 2009; 125: 158-164.
30. Weijenberg MP, Aardening PW, de Kok TM, de Goeij AF and van den Brandt PA. Cigarette smoking and KRAS oncogene mutations in sporadic colorectal cancer: results from the Netherlands Cohort Study. Mutat Res 2008; 652: 54-64.
31. Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, Anderson KE, Wolff RK and Slattery ML. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006; 98: 1731-1738.
32. Wark PA, Van der Kuil W, Ploemacher J, Van Muijen GN, Mulder CJ, Weijenberg MP, Kok FJ and Kampman E. Diet, lifestyle and risk of K-ras mutation-positive and -negative colorectal adenomas. Int J Cancer 2006; 119: 398-405.
33. Sarebo M, Skjelbred CF, Breistein R, Lothe IM, Hagen PC, Bock G, Hansteen IL and Kure EH. Association between cigarette smoking, APC mutations and the risk of developing sporadic colorectal adenomas and carcinomas. BMC Cancer 2006; 6: 71.
34. Huang CC, Cheng YW, Chen MC, Lin YS, Chou MC and Lee H. Different p53 mutation patterns in colorectal tumors from smokers and nonsmokers. Environ Mol Mutagen 2006; 47: 527-532.
35. Luchtenborg M, Weijenberg MP, Kampman E, Van Muijen GN, Roemen GMJM, Zeegers MPA, Goldbohm RA, Van’t Veer P, De Goeij AF and Van Den Brandt PA. Cigarette smoking and colorectal cancer: APC mutations, hMLH1 expression, and GSTM1 and GSTT1 polymorphisms. Am J Epidemiol 2005; 161: 806-815.
36. Diergaarde B, Vrieling A, van Kraats AA, van Muijen GN, Kok FJ and Kampman E. Cigarette smoking and genetic alterations in sporadic colon carcinomas. Carcinogenesis 2003; 24: 565-571.
37. Slattery ML, Curtin K, Ma K, Edwards S, Schaffer D, Anderson K and Samowitz W. Diet activity, and lifestyle associations with p53 mutations in colon tumors. Cancer Epidemiol Biomarkers Prev 2002; 11: 541-548.
38. Miyaki M, Iijima T, Ishii R, Kita Y, Koike M, Kuroki T and Mori T. Increased frequency of p53 mutation in sporadic colorectal cancer from cigarette smokers. Jpn J Clin Oncol 2002; 32: 196-201.
39. Wu AH, Shibata D, Yu MC, Lai MY and Ross RK. Dietary heterocyclic amines and microsatellite instability in colon adenocarcinomas. Carcinogenesis 2001; 22: 1681-1684.
40. Slattery ML, Anderson K, Curtin K, Ma KN, Schaffer D and Samowitz W. Dietary intake and microsatellite instability in colon tumors. Int J Cancer 2001; 93: 601-607.
41. Slattery ML, Anderson K, Curtin K, Ma K, Schaffer D, Edwards S and Samowitz W. Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutat Res 2001; 483: 73-81.
42. Yang P, Cunningham JM, Halling KC, Lesnick TG, Burgart LJ, Wiegert EM, Christensen ER, Lindor NM, Katzmann JA and Thibodeau SN. Higher risk of mismatch repair-deficient colorectal cancer in alpha(1)-antitrypsin deficiency carriers and cigarette smokers. Mol Genet Metab 2000; 71: 639-645.
43. Lafuente MJ, Casterad X, Trias M, Ascaso C, Molina R, Ballesta A, Zheng S, Wiencke JK and Lafuente A. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 2000; 21: 1813-1819.
44. Martinez ME, Maltzman T, Marshall JR, Einspahr J, Reid ME, Sampliner R, Ahnen DJ, Hamilton SR and Alberts DS. Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res 1999; 59: 5181-5185.
45. Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, Goldblum JR, Guillem JG, Kahi CJ, Kalady MF, O’Brien MJ, Odze RD, Ogino S, Parry S, Snover DC, Torlakovic EE, Wise PE, Young J and Church J. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012; 107: 1315-1329; quiz 1314, 1330.
46. Porta M, Crous-Bou M, Wark PA, Vineis P, Real FX, Malats N and Kampman E. Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat Res 2009; 682: 83-93.
47. Grady WM and Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135: 1079-1099.
48. Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A and Peltomaki P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 2000; 156: 1773-1779.
49. Jass JR. Towards a molecular classification of colorectal cancer. Int J Colorectal Dis 1999; 14: 194-200.
50. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R and Laird PW. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-793.
51. Goel A and Boland CR. Epigenetics of colorectal cancer. Gastroenterology 2012; 143: 1442-1460 e1441.
52. Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, Mark EJ and Kelsey KT. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001; 61: 3419-3424.
53. Jarmalaite S, Kannio A, Anttila S, Lazutka JR and Husgafvel-Pursiainen K. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer 2003; 106: 913-918.
54. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M and Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
55. Min BH, Bae JM, Lee EJ, Yu HS, Kim YH, Chang DK, Kim HC, Park CK, Lee SH, Kim KM and Kang GH. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 2011; 11: 344.
56. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB and Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96: 8681-8686.
57. Park SJ, Rashid A, Lee JH, Kim SG, Hamilton SR and Wu TT. Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol 2003; 162: 815-822.
58. Lee S, Cho NY, Yoo EJ, Kim JH and Kang GH. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med 2008; 132: 1657-1665.